Table 1.
Demographic characteristics of the study populations analyzed for the different outcome measures.
| Outcome measure and characteristics | SARAa participants (n=2400) | Control participants (n=7052) | Total population (N=9452) | P valueb | ||||||||||
| Exacerbation rate | ||||||||||||||
|
|
Gender, n (%) | |||||||||||||
|
|
|
Male | 882 (36.75) | 2851 (40.43) | 3733 (39.49) | .002 | ||||||||
|
|
|
Female | 1504 (62.67) | 4173 (59.17) | 5677 (60.06) |
|
||||||||
|
|
|
Unknown | 14 (0.58) | 28 (0.40) | 42 (0.44) |
|
||||||||
|
|
Age (years), mean (SD) | 57.7 (13.8) | 61.9 (15.3) | 60.8 (15.0) | <.001 | |||||||||
| Medication adherence | ||||||||||||||
|
|
Total group (SARA: n=1879; control: n=5460; total: n=7339) | |||||||||||||
|
|
|
Gender, n (%) | ||||||||||||
|
|
|
|
Male | 693 (36.88) | 2200 (40.29) | 2893 (39.42) | .01 | |||||||
|
|
|
|
Female | 1175 (62.53) | 3239 (59.32) | 4414 (60.14) |
|
|||||||
|
|
|
|
Unknown | 11 (0.58) | 21 (0.38) | 32 (0.44) |
|
|||||||
|
|
|
Age (years), mean (SD) | 60.9 (13.4) | 65.1 (14.5) | 64.0 (14.4) | <.001 | ||||||||
|
|
Subgroup: new usersc (SARA: n=354; control: n=1084; total: n=1438) | |||||||||||||
|
|
|
Gender, n (%) | ||||||||||||
|
|
|
|
Male | 128 (36.16) | 420 (38.74) | 548 (38.11) | .38 | |||||||
|
|
|
|
Female | 225 (63.56) | 658 (60.70) | 883 (61.40) |
|
|||||||
|
|
|
|
Unknown | 1 (0.28) | 6 (0.55) | 7 (0.49) |
|
|||||||
|
|
|
Age (years), mean (SD) | 59.4 (14.2) | 62.7 (16.5) | 61.9 (16.0) | .002 | ||||||||
|
|
Subgroup: chronic usersd (SARA: n=1525; control: n=4376; total: n=590) | |||||||||||||
|
|
|
Gender, n (%) | ||||||||||||
|
|
|
|
Male | 565 (37.05) | 1780 (40.68) | 2345 (39.74) | .02 | |||||||
|
|
|
|
Female | 950 (62.29) | 2581 (58.98) | 3531 (59.84) |
|
|||||||
|
|
|
|
Unknown | 10 (0.66) | 15 (0.34) | 25 (0.42) |
|
|||||||
|
|
|
Age (years), mean (SD) | 61.3 (13.1) | 65.7 (14.0) | 64.6 (13.9) | .04 | ||||||||
| Antimycotic treatment (SARA: n=626; control: n=1707; total: n=2333) | ||||||||||||||
|
|
Gender, n (%) | |||||||||||||
|
|
|
Male | 196 (31.31) | 612 (35.85) | 808 (34.63) | .04 | ||||||||
|
|
|
Female | 428 (68.37) | 1090 (63.85) | 1518 (65.07) |
|
||||||||
|
|
|
Unknown | 2 (0.32) | 5 (0.29) | 7 (0.30) |
|
||||||||
|
|
Age (years), mean (SD) | 55.1 (14.2) | 59.0 (16.2) | 58.0 (15.8) | <.001 | |||||||||
aSARA: Service Apothecary Respiratory Advice; in Dutch, Service Apotheek Raad en Advies.
bP values represent comparisons between the SARA group and the control group; for characteristics with multiple subcategories (ie, gender), values for the group are reported in the top row of the group.
cNew users are participants with zero R03 dispensing records in the year before the index date.
dChronic users are participants with at least one R03 dispensing record in the year before the index date.